Authorised Therapeutic exploratory (Phase II) chronic myelomonocytic Leukemia

A study with three treatments for higher-risk chronic myelomonocytic leukaemia.

EU CTIS ID: 2024-511102-22-00

What this study is testing

Main objective is the primary objective of the trial is to generate data on the efficacy by CR, mCR, or PR of the combination of the SOC agent AZA combined with venetoclax (VEN) and tagraxofusp (TAG) in the studied patient population in a descriptive manner and by statistical analysis.

Therapeutic exploratory (Phase II)

A plain-language read of the study's public EU CTIS listing. The study team confirms the details.

Who can take part

You may be able to join if

1. Signed written informed consent
10. Women of childbearing potential and practicing a highly effective method of birth control according to the Clinical Trial Facilitation Coordination Group Recommendation (Version 1.1, 2020)3: • combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: o oral o intravaginal o transdermal • progestogen-only hormonal contraception associated with inhibition of ovulation: o oral o injectable o implantable • intrauterine device (IUD) • intrauterine hormone-releasing system (IUS) • bilateral tubal occlusion • vasectomised partner • sexual abstinence For females, these requirements apply during the treatment period and for 6 months after the end of dosing.
11. A woman of childbearing potential must have a negative serum (β-human chorionic gonadotropin [β-hCG]) pregnancy test within one week of treatment initiation and agree to be tested (serum or urine) on day 1 of every cycle and at EOT
12. A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a highly effective method of contraception) and all men must also not donate sperm. Highly effective methods of contraception include double-barrier contraception, total abstinence, vasectomization with confirmed azoospermia, female partner with an intrauterine device, etc.). For males, these requirements apply during the study treatment period and for 3 months after the end of dosing.
2. Male and female ≥ 18 years at date of signing informed consent
3. Must be able to adhere to the study visit schedule and other protocol requirements

You likely can't join if

1. CMML with t (5 ;12) or PDGFRB rearrangement that may be treated with imatinib
10. Serious concomitant systemic disorder, including active bacterial, fungal, psychiatric illness, or viral infection that in the opinion of the investigator, would compromise the safety of the patient and/or his/her ability to complete the study.
11. Medical condition requiring therapies with CYP3A inducing activity. All CYP3A inducers should be discontinued 7 days prior to the first dose of study drug
12. Patients with known CNS involvement
13. Females who are pregnant or are currently breastfeeding or planning to become pregnant while enrolled in this study or within 6 months after the end of dosing
14. Patient is a man who plans to father a child while enrolled in this study or within 3 months after the end of dosing

See the full eligibility criteria

Who can join

1. Signed written informed consent
10. Women of childbearing potential and practicing a highly effective method of birth control according to the Clinical Trial Facilitation Coordination Group Recommendation (Version 1.1, 2020)3: • combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: o oral o intravaginal o transdermal • progestogen-only hormonal contraception associated with inhibition of ovulation: o oral o injectable o implantable • intrauterine device (IUD) • intrauterine hormone-releasing system (IUS) • bilateral tubal occlusion • vasectomised partner • sexual abstinence For females, these requirements apply during the treatment period and for 6 months after the end of dosing.
11. A woman of childbearing potential must have a negative serum (β-human chorionic gonadotropin [β-hCG]) pregnancy test within one week of treatment initiation and agree to be tested (serum or urine) on day 1 of every cycle and at EOT
12. A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a highly effective method of contraception) and all men must also not donate sperm. Highly effective methods of contraception include double-barrier contraception, total abstinence, vasectomization with confirmed azoospermia, female partner with an intrauterine device, etc.). For males, these requirements apply during the study treatment period and for 3 months after the end of dosing.
2. Male and female ≥ 18 years at date of signing informed consent
3. Must be able to adhere to the study visit schedule and other protocol requirements
4. CMML diagnosis according to WHO 2022 criteria
5. CPSS risk intermediate-2 or high2 (HR) CMML at study entry (WBC prior to HY used to compute CPSS at inclusion in HY-exposed patients, see below)
6. Patients who are eligible for and will receive azacitidine (AZA) as per standard of care.
7. Performance status 0-2 on the Eastern Cooperative Oncology Group (ECOG) Scale
8. Adequate organ function including the following: • Liver: o Total bilirubin < 1.5 times upper limit of normal (ULN) (except moderate unconjugated hyperbilirubinemia due to intra medullary hemolysis or due to Gilbert syndrome), AND o Alanine transaminase (ALT) and aspartate transaminase (AST) < 2.5 times ULN • Renal: Creatinine clearance >/= 45 mL/minute • Cardiac o Left ventricular ejection fraction (LVEF) ≥ 50% by multigated acquisition scan (MUGA) or 2-dimensional (2-D) echocardiogram (ECHO) within 28 days prior to the start of therapy o No clinically significant abnormalities on a 12-lead electrocardiogram (ECG) • Albumin: Serum albumin ≥ 3.2 g/dL (note: albumin infusions are not permitted in order to enable eligibility)
9. Availability of blood counts and transfusion events for previous 8 weeks

What rules you out

1. CMML with t (5 ;12) or PDGFRB rearrangement that may be treated with imatinib
10. Serious concomitant systemic disorder, including active bacterial, fungal, psychiatric illness, or viral infection that in the opinion of the investigator, would compromise the safety of the patient and/or his/her ability to complete the study.
11. Medical condition requiring therapies with CYP3A inducing activity. All CYP3A inducers should be discontinued 7 days prior to the first dose of study drug
12. Patients with known CNS involvement
13. Females who are pregnant or are currently breastfeeding or planning to become pregnant while enrolled in this study or within 6 months after the end of dosing
14. Patient is a man who plans to father a child while enrolled in this study or within 3 months after the end of dosing
15. The patient is receiving immunosuppressive therapy for any reason, with the exception of low-dose prednisone (≤ 10 mg/day) or equivalent
16. The patient has persistent clinically significant toxicities Grade ≥ 2 from previous therapies, including cytotoxic chemotherapy, targeted therapies, biological therapies, or immunotherapies, not readily controlled by supportive measures (excluding alopecia, nausea, and fatigue)
17. The patient has clinically significant cardiovascular disease (e.g. uncontrolled or any New York Heart Association Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial infarction, unstable angina or stroke within 6 months prior to study entry, uncontrolled hypertension or clinically significant arrhythmias not controlled by medication).
18. The patient has uncontrolled, clinically significant pulmonary disease (e.g. chronic obstructive pulmonary disease, pulmonary hypertension) that in the opinion of the Investigator would put the patient at significant risk for pulmonary complications during the study.
19. The patient has known positive status for human immunodeficiency virus (HIV) or active or chronic Hepatitis B or Hepatitis C.
2. Myeloproliferative / myelodysplastic neoplasm other than CMML
20. Patient is unable to attend site visits as patient is in custody by order of an authority or a court of law
21. Participation in another interventional clinical study within the last 3 months prior to signing the ICF or simultaneous participation in other clinical studies
22. Previous assignment to treatment during this study
23. Close affiliation with the investigator (e.g. a close relative) or persons working at the study site
24. Patient is an employee of the sponsor or involved CRO
25. Criteria which in the opinion of the investigator preclude participation for scientific reasons, for reasons of compliance, or for reasons of the patient’s safety
3. Bone marrow or peripheral blood blasts (including promonocytes) ≥ 20%
4. Patients with unavailable CPSS at inclusion (WBC prior to HY used to compute CPSS at inclusion in HY-exposed patients) or with a CPSS low or intermediate-1 at study entry
5. Patient has received an experimental or investigational drug or used an invasive investigational medical device within 14 days prior to day 1 of C1
6. Prior treatment with TAG, VEN and/or HMA treatment, including AZA/CC-486, decitabine (DEC), SGI-110, AST7227. Prior treatment with Erythropoiesis Stimulating Agents (ESA) or hydroxyurea (HY) is acceptable, with a > 15 days washout from ESAs and > 3 days washout from HY
7. Patients who previously received an allogeneic stem cell transplantation (HSCT) for CMML or an antecedent hematological malignancy. Those never transplanted but eligible for HSCT are eligible for the trial.
8. Major surgery within 4 weeks prior to day 1 of C1 (excluding the placement of vascular access and other minor surgical procedures)
9. Prior malignancy (except in situ cervix carcinoma, limited basal cell carcinoma, asymptomatic prostatic cancer not requiring treatment, or other tumors if not active during the last 2 years)

The study team makes the final eligibility decision.

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.

Explore other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH)Heart failure Coronary artery disease

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.